Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report

被引：1

作者：

Ikeo, Satoshi ^{[1
,2
,3
]}

Yasuda, Naoaki ^{[1
]}

Sakai, Yuki ^{[1
]}

Hayashi, Yasuyuki ^{[1
]}

Sokai, Akihiko ^{[1
]}

Iwata, Toshiyuki ^{[1
]}

Nishimura, Takashi ^{[1
]}

机构：

[1] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan

[3] Kyoto Katsura Hosp, Dept Resp Med, 17 Yamadahiraocho,Nishikyo Ku, Kyoto 6158256, Japan

来源：

THORACIC CANCER | 2023年 / 14卷 / 10期

基金：

日本学术振兴会;

关键词：

lung cancer; MET exon 14 skipping; tepotinib; transient asymptomatic pulmonary opacities; OSIMERTINIB; AMPLIFICATION; MUTATIONS;

D O I：

10.1111/1759-7714.14831

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET-TKIs) have been approved for the treatment of non-small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (EGFR)-TKIs have been reported. Here, we report a case wherein ground-glass opacities (GGOs) appeared during the course of treatment with tepotinib, a MET-TKI, but spontaneously resolved with drug withdrawal, after which treatment was resumed with a reduced dose. Although there have been no reports of TAPOs with MET-TKIs, the clinical and imaging findings of this case were consistent with TAPOs. For TAPOs occurring because of MET-TKI, the drug can be continued under careful observation even if GGOs appear.

引用

页码：958 / 960

页数：3

共 50 条

[1] MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Heist, Rebecca S.
Shim, Hyo Sup
Gingipally, Shalini
Mino-Kenudson, Mari
Le, Long
Gainor, Justin F.
Zheng, Zongli
Aryee, Martin
Xia, Junfeng
Jia, Peilin
Jin, Hailing
Zhao, Zhongming
Pao, Gwilliam
Engelman, Jeffrey A.
Iafrate, A. John
ONCOLOGIST, 2016, 21 (04): : 481 - 486
[2] Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
Chen, Zhuxing
Zhu, Feng
Li, Caichen
Li, Jianfu
Cheng, Bo
Xiong, Shan
Zhong, Ran
Liang, Wenhua
He, Jianxing
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
[3] Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report
Zhang, Yu
Zhang, Hao
Wang, Hanqing
Zeng, Jingtong
Zhang, Bo
Zhou, Ning
Zu, Lingling
Song, Zuoqing
Wang, Changli
Xu, Song
FRONTIERS IN ONCOLOGY, 2022, 12
[4] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Salgia, Ravi
Sattler, Martin
Scheele, Juergen
Stroh, Christopher
Felip, Enriqueta
CANCER TREATMENT REVIEWS, 2020, 87
[5] Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
Huang, Caiwen
Zou, Qihua
Liu, Hui
Qiu, Bo
Li, Qiwen
Lin, Yongbin
Liang, Ying
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)
[6] Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
Caiwen Huang
Qihua Zou
Hui Liu
Bo Qiu
Qiwen Li
Yongbin Lin
Ying Liang
Current Treatment Options in Oncology, 2020, 21
[7] Intertumoral Molecular Heterogeneity of Non-small Cell Lung Cancer with MET Exon 14 Skipping
Han, Y.
Chen, S.
Xiang, C.
Guo, L.
Zhu, L.
Shao, J.
Hu, T.
Wang, J.
Zhu, C.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S60 - S61
[8] Identification of a Novel MET Exon 14 Skipping Variant in Non-Small Cell Lung Cancer
Cheng, Y.
Das, R.
Jakubowski, M.
Spildener, J.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S89 - S89
[9] Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer
Wu, Xue
Zhang, Yaru
Pang, Jiaohui
Lin, Li
Yin, Jiani C.
Tang, Haimeng
Shao, Yang
CANCER RESEARCH, 2023, 83 (07)
[10] Non-small cell lung cancer with MET exon 14 skip mutation: case report
Clough, Wolfgang
Al Jaberi, Mira
Dalia, Samir
ANNALS OF TRANSLATIONAL MEDICINE, 2022,

← 1 2 3 4 5 →